



# ASX Release

EMvision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

## EMV APPOINTS CEO DR RON WEINBERGER MANAGING DIRECTOR

**EMVision Medical Devices Limited (ASX:EMV)** (“**EMVision**” or the “**Company**”), a medical device company focused on the development and commercialisation of portable medical imaging technology, is pleased to provide an update on its Board composition following its encouraging preliminary stroke patient images.

Today the following Board changes become effective:

- **Dr Ron Weinberger**, EMVision's CEO and senior medical device executive has been appointed to the Board of the Company as Managing Director. Dr Weinberger has a proven record in developing significant shareholder value at multiple levels in the medical device industry. Dr Weinberger is the former Chief Executive Officer and Executive Director of Nanosonics (ASX:NAN), a \$1.9 billion market cap healthcare company and has extensive experience commercialising medical devices; and
- **John Keep**, EMVision's Executive Chairman has transitioned to the role of Non-Executive Chairman, in line with best practice governance.

EMVision Chairman, John Keep, commented “Ron’s appointment follows the positive outcomes achieved thus far in our pilot clinical trial. Ron’s deep expertise in product development and innovation has been invaluable to EMVision. We look forward to Ron’s ongoing leadership in this incredibly exciting next stage of EMVision’s growth and strategic development.”

EMVision CEO and Managing Director, Dr Ron Weinberger, commented “I am honoured to join the Board of EMVision. We have reached some exciting milestones and there is substantial opportunity ahead. We are fortunate to work with outstanding teams at the University of Queensland, Princess Alexandra Hospital, Tiller Design, as well as excellent clinical advisors and collaborators. This integration of effort is the heart of our success to date and we will continue to deliver in the future.”

In accordance with ASX listing rule 3.16.4 the Company advises of the following material variation to the terms of engagement of Dr Ron Weinberger as a result of the appointment. The Company has granted the following options subject to any required shareholder approval at the next shareholder meeting:

1,000,000 options over ordinary shares with an exercise price of \$1.25 and an expiry date of 6 May 2023, with the following vesting conditions: 50% vest 12 months from the grant date and 50% 24 months from the grant date.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills  
Investor & Media Relations  
+61 468 385 208  
michael@spring-communications.com.au

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

### **About EMVision Medical Devices**

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.9 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

### **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.